{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:04:33Z","timestamp":1792825473895,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Population-based research examining geographic variability in psychotropic medication dispensing to children and youth and the sociodemographic correlates of such variation is lacking. Variation in psychotropic use could reflect disparities in access to non-pharmacologic interventions and identify potentially concerning use patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a population-based study of all Ontario residents aged 0 to 24\u2009years who were dispensed a benzodiazepine, stimulant, antipsychotic or antidepressant between January 1, 2018, and December 31, 2018. We conducted small-area variation analyses and identified determinants of dispensing using negative binomial generalized estimating equation models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The age- and sex-standardized rate of psychotropic dispensing to children and youth was 76.8 (range 41.7 to 144.4) prescriptions per 1000 population, with large variation in psychotropic dispensing across Ontario\u2019s census divisions. Males had higher antipsychotic [rate ratio (RR) 1.40; 95% confidence interval (CI) 1.36 to 1.44) and stimulant (RR 1.75; 95% CI 1.70 to 1.80) dispensing rates relative to females, with less use of benzodiazepines (RR 0.85; 95% CI 0.83 to 0.88) and antidepressants (RR 0.81; 95% CI 0.80 to 0.82). Lower antipsychotic dispensing was observed in the highest income neighbourhoods (RR 0.72; 95% CI 0.70 to 0.75) relative to the lowest. Benzodiazepine (RR 1.12; 95% CI 1.01 to 1.24) and stimulant (RR 1.11; 95% CI 1.01 to 1.23) dispensing increased with the density of mental health services in census divisions, whereas antipsychotic use decreased (RR 0.82; 95% CI 0.73 to 0.91). The regional density of child and adolescent psychiatrists and developmental pediatricians (RR 1.00; 95% CI 0.99 to 1.01) was not associated with psychotropic dispensing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We found significant variation in psychotropic dispensing among young Ontarians. Targeted investment in regions with long wait times for publicly-funded non-pharmacological interventions and novel collaborative service models may minimize variability and promote best practices in using psychotropics among children and youth.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-022-14677-6","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T06:05:16Z","timestamp":1673417116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study"],"prefix":"10.1186","volume":"23","author":[{"given":"Tony","family":"Antoniou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Pajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yona","family":"Lunsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Penner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"14677_CR1","first-page":"3","volume":"32","author":"J Servais","year":"2021","unstructured":"Servais J, Ramage-Morin PL, Gal J, Hales CM. Prescription medication use among Canadian children and youth, 2012 to 2017. Health Rep. 2021;32:3\u201316.","journal-title":"Health Rep"},{"key":"14677_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1089\/cap.2019.0018","volume":"29","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Stewart DG, Chan P, Tehrani A, Patten SB. The Pharmacoepidemiology of psychotropic medication use in Canadian children from 2012 to 2016. J Child Adolesc Psychopharmacol. 2019;29:740\u20135.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"14677_CR3","doi-asserted-by":"publisher","first-page":"e1003215","DOI":"10.1371\/journal.pmed.1003215","volume":"17","author":"RH Jack","year":"2020","unstructured":"Jack RH, Hollis C, Coupland C, Morriss R, Knaggs RD, Butler D, et al. Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: a population-based cohort study. PLoS Med. 2020;17:e1003215.","journal-title":"PLoS Med"},{"key":"14677_CR4","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00213-021-05809-8","volume":"238","author":"A G\u00f3mez-Lumbreras","year":"2021","unstructured":"G\u00f3mez-Lumbreras A, Garcia Sangenis A, Prat Vallverd\u00fa O, Gatell Carb\u00f3 A, Vedia Urgell C, Gisbert Gustemps L, et al. Psychotropic use in children and adolescents in Scandinavia and Catalonia: a 10-year population-based study. Psychopharmacology. 2021;238:1805\u201315.","journal-title":"Psychopharmacology"},{"key":"14677_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00787-014-0631-y","volume":"24","author":"HC Steinhausen","year":"2015","unstructured":"Steinhausen HC. Recent international trends in psychotropic medication prescriptions for children and adolescents. Eur Child Adolesc Psychiatry. 2015;24:635\u201340.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"14677_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0706743716661325","volume":"62","author":"P Kurdyak","year":"2017","unstructured":"Kurdyak P, Zaheer J, Cheng J, Rudoler D, Mulsant BH. Changes in characteristics and practice patterns of Ontario psychiatrists. Can J Psychiatr. 2017;62:40\u20137.","journal-title":"Can J Psychiatr"},{"key":"14677_CR7","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1176\/ps.2009.60.10.1323","volume":"60","author":"KC Thomas","year":"2009","unstructured":"Thomas KC, Ellis AR, Konrad TR, Holzer CE, Morrissey JP. County-level estimates of mental health professional shortage in the United States. Psychiatr Serv. 2009;60:1323\u20138.","journal-title":"Psychiatr Serv"},{"key":"14677_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/0269881116636107","volume":"30","author":"AN Sharma","year":"2016","unstructured":"Sharma AN, Arango C, Coghill D, Gringras P, Nutt DJ, Pratt P, et al. BAP position statement: off-label prescribing of psychotropic medication to children and adolescents. J Psychopharmacol. 2016;30:416\u201321.","journal-title":"J Psychopharmacol"},{"key":"14677_CR9","first-page":"238","volume":"24","author":"E Leckman-Westin","year":"2018","unstructured":"Leckman-Westin E, Finnerty M, Scholle SH, Pritam R, Layman D, Kealey E, et al. Differences in Medicaid antipsychotic medication measures among children with SSI, Foster Care, and income-based aid. J Manag Care Spec Pharm. 2018;24:238\u201346.","journal-title":"J Manag Care Spec Pharm"},{"key":"14677_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neubiorev.2021.06.001","volume":"128","author":"R Massuti","year":"2021","unstructured":"Massuti R, Moreira-Maia CR, Campani F, S\u00f4nego M, Amaro J, Akutagava-Martins GC, et al. Assessing undertreatment and overtreatment\/misuse of ADHD medications in children and adolescents across continents: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;128:64\u201373.","journal-title":"Neurosci Biobehav Rev"},{"key":"14677_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaac.2015.09.020","volume":"55","author":"M Finnerty","year":"2016","unstructured":"Finnerty M, Neese-Todd S, Pritam R, Leckman-Westin E, Bilder S, Byron SC, et al. Access to psychosocial services prior to starting antipsychotic treatment among Medicaid-insured youth. J Am Acad Child Adolesc Psychiatry. 2016;55:69\u201376.e3.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"14677_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1176\/appi.ps.201100329","volume":"63","author":"E Harris","year":"2012","unstructured":"Harris E, Sorbero M, Kogan JN, Schuster J, Stein BD. Concurrent mental health therapy among Medicaid-enrolled youths starting antipsychotic medications. Psychiatr Serv. 2012;63:351\u20136.","journal-title":"Psychiatr Serv"},{"key":"14677_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0033354920932658","volume":"135","author":"PM Harati","year":"2020","unstructured":"Harati PM, Cummings JR, Serban N. Provider-level caseload of psychosocial services for Medicaid-insured children. Public Health Rep. 2020;135:599\u2013610.","journal-title":"Public Health Rep"},{"key":"14677_CR14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1176\/appi.ps.004442012","volume":"64","author":"DC McDonald","year":"2013","unstructured":"McDonald DC, Jalbert SK. Geographic variation and disparity in stimulant treatment of adults and children in the United States in 2008. Psychiatr Serv. 2013;64:1079\u201386.","journal-title":"Psychiatr Serv"},{"key":"14677_CR15","doi-asserted-by":"publisher","first-page":"e0206100","DOI":"10.1371\/journal.pone.0206100","volume":"13","author":"BJ Piper","year":"2018","unstructured":"Piper BJ, Ogden CL, Simoyan OM, Chung DY, Caggiano JF, Nichols SD, et al. Trends in use of prescription stimulants in the United States and territories, 2006 to 2016. PLoS One. 2018;13:e0206100.","journal-title":"PLoS One"},{"key":"14677_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.socscimed.2004.06.002","volume":"60","author":"SJ Lin","year":"2005","unstructured":"Lin SJ, Crawford SY, Lurvey PL. Trend and area variation in amphetamine prescription usage among children and adolescents in Michigan. Soc Sci Med. 2005;60:617\u201326.","journal-title":"Soc Sci Med"},{"key":"14677_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1542\/peds.111.2.237","volume":"111","author":"ER Cox","year":"2003","unstructured":"Cox ER, Motheral BR, Henderson RR, Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics. 2003;111:237\u201343.","journal-title":"Pediatrics."},{"key":"14677_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1087054719883008","volume":"24","author":"IE Tseregounis","year":"2020","unstructured":"Tseregounis IE, Stewart SL, Crawford A, Marshall BDL, Cerd\u00e1 M, Shev AB, et al. Age- and sex-specific increases in stimulant prescribing rates-California, 2008-2017. J Atten Disord. 2020;24:205\u201314.","journal-title":"J Atten Disord"},{"key":"14677_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1089\/cap.2005.15.62","volume":"15","author":"LA Habel","year":"2005","unstructured":"Habel LA, Schaefer CA, Levine P, Bhat AK, Elliott G. Treatment with stimulants among youths in a large California health plan. J Child Adolesc Psychopharmacol. 2005;15:62\u20137.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"14677_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/1077559509360916","volume":"15","author":"R Raghavan","year":"2010","unstructured":"Raghavan R, Lama G, Kohl P, Hamilton B. Interstate variations in psychotropic medication use among a national sample of children in the child welfare system. Child Maltreat. 2010;15:121\u201331.","journal-title":"Child Maltreat"},{"key":"14677_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.chiabu.2011.01.012","volume":"35","author":"LK Leslie","year":"2011","unstructured":"Leslie LK, Raghavan R, Hurley M, Zhang J, Landsverk J, Aarons G. Investigating geographic variation in use of psychotropic medications among youth in child welfare. Child Abuse Negl. 2011;35:333\u201342.","journal-title":"Child Abuse Negl"},{"key":"14677_CR22","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.childyouth.2012.04.006","volume":"34","author":"D Rubin","year":"2012","unstructured":"Rubin D, Matone M, Huang YS, Feudtner C, Localio R. Interstate variation in trends of psychotropic medication use among Medicaid-enrolled children in foster care. Child Youth Serv Rev. 2012;34:1492\u20139.","journal-title":"Child Youth Serv Rev"},{"key":"14677_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1176\/appi.ps.201700260","volume":"69","author":"R Soria Saucedo","year":"2018","unstructured":"Soria Saucedo R, Liu X, Hincapie-Castillo JM, Zambrano D, Bussing R, Winterstein AG. Prevalence, time trends, and utilization patterns of psychotropic Polypharmacy among pediatric Medicaid beneficiaries, 1999-2010. Psychiatr Serv. 2018;69:919\u201326.","journal-title":"Psychiatr Serv"},{"key":"14677_CR24","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s12888-021-03533-3","volume":"21","author":"M Candon","year":"2021","unstructured":"Candon M, Shen S, Fadeyibi O, Smith JL, Rothbard A. Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018. BMC Psychiatry. 2021;21:524.","journal-title":"BMC Psychiatry"},{"key":"14677_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaac.2020.09.023","volume":"60","author":"GA Bushnell","year":"2021","unstructured":"Bushnell GA, Crystal S, Olfson M. Trends in antipsychotic medication use in young privately insured children. J Am Acad Child Adolesc Psychiatry. 2021;60:877\u201386.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"14677_CR26","unstructured":"Ministry of Health and Long-Term Care. OHIP+: Children and Youth Pharmacare Key Facts for Prescribers. Available at: https:\/\/www.afhto.ca\/wp-content\/uploads\/ohip_prescriber-002.pdf. Accessed 2 June 2022."},{"key":"14677_CR27","unstructured":"Statistics Canada. Focus on Geography Series, 2016 Census. Available at: https:\/\/www12.statcan.gc.ca\/census-recensement\/2016\/as-sa\/fogs-spg\/Index-eng.cfm. Accessed 2 June 2022."},{"key":"14677_CR28","unstructured":"Statistics Canada. Census Profile, 2016 Census. Available at: https:\/\/www12.statcan.gc.ca\/census-recensement\/2016\/dp-pd\/prof\/search-recherche\/lst\/results-resultats.cfm?Lang=E&TABID=1&G=1&Geo1=&Code1=&Geo2=&Code2=&GEOCODE=35&type=0. Accessed 2 June 2022."},{"key":"14677_CR29","first-page":"741","volume":"24","author":"P Diehr","year":"1990","unstructured":"Diehr P, Cain K, Connell F, Volinn E. What is too much variation? The null hypothesis in small-area analysis. Health Serv Res. 1990;24:741\u201371.","journal-title":"Health Serv Res"},{"key":"14677_CR30","unstructured":"Appleby J, Raleigh V, Frosini F, Bevan G, Gao H, Lyscom T. Variations in Health Care: the Good, the Bad and the Inexplicable. Available at: http:\/\/www.kingsfund.org.uk\/sites\/files\/kf\/field\/field_publication_file\/Variations-in-health-care-good-bad-inexplicable-report-The-Kings-Fund-April-2011.pdf. Accessed 12 Apr 2022."},{"key":"14677_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"KY Liang","year":"1986","unstructured":"Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13\u201322.","journal-title":"Biometrika."},{"key":"14677_CR32","unstructured":"The Johns Hopkins ACG System (Johns Hopkins University, Baltimore) Available: www.hopkinsacg.org. Accessed 15 Apr 2022."},{"key":"14677_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/cap.2017.0077","volume":"28","author":"RS Sultan","year":"2018","unstructured":"Sultan RS, Correll CU, Schoenbaum M, King M, Walkup JT, Olfson M. National Patterns of commonly prescribed psychotropic medications to young people. J Child Adolesc Psychopharmacol. 2018;28:158\u201365.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"14677_CR34","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry. 2015;72:867\u201374.","journal-title":"JAMA Psychiatry"},{"key":"14677_CR35","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1089\/cap.2015.0228","volume":"26","author":"M Olfson","year":"2016","unstructured":"Olfson M, King M, Schoenbaum M. Stimulant treatment of young people in the United States. J Child Adolesc Psychopharmacol. 2016;26:520\u20136.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"14677_CR36","doi-asserted-by":"publisher","first-page":"e1002635","DOI":"10.1371\/journal.pmed.1002635","volume":"15","author":"A Sidorchuk","year":"2018","unstructured":"Sidorchuk A, Isomura K, Molero Y, Hellner C, Lichtenstein P, Chang Z, et al. Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study. PLoS Med. 2018;15:e1002635.","journal-title":"PLoS Med"},{"key":"14677_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1177\/0706743716649190","volume":"61","author":"N Arora","year":"2016","unstructured":"Arora N, Knowles S, Gomes T, Mamdani MM, Juurlink DN, Carlisle C, et al. Interprovincial variation in antipsychotic and antidepressant prescriptions dispensed in the Canadian pediatric population. Can J Psychiatr. 2016;61:758\u201365.","journal-title":"Can J Psychiatr"},{"key":"14677_CR38","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamapediatrics.2021.5634","volume":"176","author":"C Leong","year":"2022","unstructured":"Leong C, Katz LY, Bolton JM, Enns MW, Delaney J, Tan Q, et al. Psychotropic drug use in children and adolescents before and during the COVID-19 pandemic. JAMA Pediatr. 2022;176:318\u201320.","journal-title":"JAMA Pediatr"},{"key":"14677_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/cap.2019.0032","volume":"30","author":"ZA Barczyk","year":"2020","unstructured":"Barczyk ZA, Rucklidge JJ, Eggleston M, Mulder RT. Psychotropic medication prescription rates and trends for New Zealand children and adolescents 2008-2016. J Child Adolesc Psychopharmacol. 2020;30:87\u201396.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"14677_CR40","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/pds.3649","volume":"23","author":"F Hoffmann","year":"2014","unstructured":"Hoffmann F, Glaeske G, Bachmann CJ. Trends in antidepressant prescriptions for children and adolescents in Germany from 2005 to 2012. Pharmacoepidemiol Drug Saf. 2014;23:1268\u201372.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"14677_CR41","doi-asserted-by":"publisher","first-page":"e3784","DOI":"10.1097\/MD.0000000000003784","volume":"95","author":"M Sohn","year":"2016","unstructured":"Sohn M, Moga DC, Blumenschein K, Talbert J. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore). 2016;95:e3784.","journal-title":"Medicine (Baltimore)"},{"key":"14677_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00787-022-01950-7","volume":"31","author":"PJ Hoekstra","year":"2022","unstructured":"Hoekstra PJ, Dietrich A. First do no harm: use off-label antipsychotic medication in children and adolescents with great caution. Eur Child Adolesc Psychiatry. 2022;31:1\u20133.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"14677_CR43","first-page":"218","volume":"20","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Panagiotopoulos C, Davidson J, Ho J. CAMESA guideline group. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20:218\u201333 Erratum in: J Can Acad Child Adolesc Psychiatry 2011;20:1\u20132.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"14677_CR44","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","volume":"76","author":"WA Ray","year":"2019","unstructured":"Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, et al. Association of Antipsychotic Treatment with Risk of unexpected death among children and youths. JAMA Psychiatry. 2019;76:162\u201371.","journal-title":"JAMA Psychiatry"},{"key":"14677_CR45","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archpedi.161.9.857","volume":"161","author":"TE Froehlich","year":"2007","unstructured":"Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit\/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161:857\u201364.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"14677_CR46","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaac.2020.05.005","volume":"59","author":"HJ Walter","year":"2020","unstructured":"Walter HJ, Bukstein OG, Abright AR, Keable H, Ramtekkar U, Ripperger-Suhler J, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020;59:1107\u201324.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 2S","key":"14677_CR47","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1097\/DBP.0000000000000770","volume":"41","author":"WJ Barbaresi","year":"2020","unstructured":"Barbaresi WJ, Campbell L, Diekroger EA, Froehlich TE, Liu YH, O'Malley E, et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the assessment and treatment of children and adolescents with complex attention-deficit\/hyperactivity disorder. J Dev Behav Pediatr. 2020;41(Suppl 2S):S35\u201357.","journal-title":"J Dev Behav Pediatr"},{"key":"14677_CR48","doi-asserted-by":"publisher","first-page":"e20192528","DOI":"10.1542\/peds.2019-2528","volume":"144","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, et al. Subcommittee on children and adolescents with attention-deficit\/hyperactive disorder. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144:e20192528.","journal-title":"Pediatrics."},{"key":"14677_CR49","unstructured":"Children\u2019s Mental Health Ontario. Kids can\u2019t wait: 2020 report on wait lists and wait times for child and youth mental health care in Ontario. Available at: https:\/\/cmho.org\/wp-content\/uploads\/CMHO-Report-WaitTimes-2020.pdf. Accessed 2 June 2022."},{"key":"14677_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12910-017-0179-8","volume":"18","author":"C FitzGerald","year":"2017","unstructured":"FitzGerald C, Hurst S. Implicit bias in healthcare professionals: a systematic review. BMC Med Ethics. 2017;18:19.","journal-title":"BMC Med Ethics"},{"key":"14677_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40596-019-01127-6","volume":"44","author":"MC Fadus","year":"2020","unstructured":"Fadus MC, Ginsburg KR, Sobowale K, Halliday-Boykins CA, Bryant BE, Gray KM, et al. Unconscious Bias and the diagnosis of disruptive behavior disorders and ADHD in African American and Hispanic youth. Acad Psychiatry. 2020;44:95\u2013102.","journal-title":"Acad Psychiatry"},{"key":"14677_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/nyas.14687","volume":"1508","author":"TJ Sabol","year":"2022","unstructured":"Sabol TJ, Kessler CL, Rogers LO, Petitclerc A, Silver J, Briggs-Gowan M, et al. A window into racial and socioeconomic status disparities in preschool disciplinary action using developmental methodology. Ann N Y Acad Sci. 2022;1508:123\u201336.","journal-title":"Ann N Y Acad Sci"},{"key":"14677_CR53","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1037\/h0079361","volume":"62","author":"MA Mason","year":"1992","unstructured":"Mason MA, Gibbs JT. Patterns of adolescent psychiatric hospitalization: implications for social policy. Am J Orthop. 1992;62:447\u201357.","journal-title":"Am J Orthop"},{"key":"14677_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.17744\/mehc.31.1.u82021637276wv1k","volume":"31","author":"K Feisthamel","year":"2009","unstructured":"Feisthamel K, Schwartz R. Differences in mental health counselors' diagnoses based on client race: an investigation of adjustment, childhood, and substance-related disorders. J Ment Health Couns. 2009;31:47\u201359.","journal-title":"J Ment Health Couns"},{"key":"14677_CR55","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s10803-006-0314-8","volume":"37","author":"DS Mandell","year":"2007","unstructured":"Mandell DS, Ittenbach RF, Levy SE, Pinto-Martin JA. Disparities in diagnoses received prior to a diagnosis of autism spectrum disorder. J Autism Dev Disord. 2007;37:1795\u2013802.","journal-title":"J Autism Dev Disord"},{"key":"14677_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/0145935X.2011.605315","volume":"32","author":"L Mizock","year":"2011","unstructured":"Mizock L, Harkins D. Diagnostic bias and conduct disorder: improving culturally sensitive diagnosis. Child Youth Serv. 2011;32:243\u201353.","journal-title":"Child Youth Serv"},{"key":"14677_CR57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40359-016-0136-1","volume":"4","author":"B Grinde","year":"2016","unstructured":"Grinde B, Tambs K. Effect of household size on mental problems in children: results from the Norwegian mother and child cohort study. BMC Psychol. 2016;4:31.","journal-title":"BMC Psychol"},{"key":"14677_CR58","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00127-011-0405-5","volume":"47","author":"DV Riordan","year":"2012","unstructured":"Riordan DV, Morris C, Hattie J, Stark C. Family size and perinatal circumstances, as mental health risk factors in a Scottish birth cohort. Soc Psychiatry Psychiatr Epidemiol. 2012;47:975\u201383.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"14677_CR59","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/bmjebm-2018-111133","volume":"24","author":"U Hoang","year":"2019","unstructured":"Hoang U, James AC, Liyanage H, Jones S, Joy M, Blair M, et al. Determinants of inter-practice variation in ADHD diagnosis and stimulant prescribing: cross-sectional database study of a national surveillance network. BMJ Evid Based Med. 2019;24:155\u201361.","journal-title":"BMJ Evid Based Med"},{"key":"14677_CR60","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/1753-6405.12269","volume":"39","author":"M Ghosh","year":"2015","unstructured":"Ghosh M, Holman CD, Preen DB. Exploring parental country of birth differences in the use of psychostimulant medications for ADHD: a whole-population linked data study. Aust N Z J Public Health. 2015;39:88\u201392.","journal-title":"Aust N Z J Public Health"},{"key":"14677_CR61","doi-asserted-by":"publisher","first-page":"e000477","DOI":"10.1136\/bmjopen-2011-000477","volume":"2","author":"H Knopf","year":"2012","unstructured":"Knopf H, H\u00f6lling H, Huss M, Schlack R. Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: results of the German health interview and examination survey (KiGGS). BMJ Open. 2012;2:e000477.","journal-title":"BMJ Open"},{"key":"14677_CR62","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00127-009-0123-4","volume":"45","author":"LC Wittkampf","year":"2010","unstructured":"Wittkampf LC, Smeets HM, Knol MJ, Geerlings MI, Braam AW, De Wit NJ. Differences in psychotropic drug prescriptions among ethnic groups in the Netherlands. Soc Psychiatry Psychiatr Epidemiol. 2010;45:819\u201326.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"14677_CR63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13034-017-0152-9","volume":"11","author":"M Ghosh","year":"2017","unstructured":"Ghosh M, Holman CDJ, Preen DB. Identifying cross-cultural variations in psychostimulant use for attention deficit hyperactivity disorder using linked data. Child Adolesc Psychiatry Ment Health. 2017;11:16.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"14677_CR64","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1176\/appi.ps.201700547","volume":"69","author":"J Thackeray","year":"2018","unstructured":"Thackeray J, Crane D, Fontanella C, Sorter M, Baum R, Applegate M. A Medicaid quality improvement collaborative on psychotropic medication prescribing for children. Psychiatr Serv. 2018;69:501\u20134.","journal-title":"Psychiatr Serv"},{"key":"14677_CR65","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1176\/appi.ps.201900417","volume":"71","author":"KJ Kelleher","year":"2020","unstructured":"Kelleher KJ, Rubin D, Hoagwood K. Policy and practice innovations to improve prescribing of psychoactive medications for children. Psychiatr Serv. 2020;71:706\u201312.","journal-title":"Psychiatr Serv"},{"key":"14677_CR66","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/CJRM.CJRM_20_18","volume":"24","author":"AD Furlan","year":"2019","unstructured":"Furlan AD, Pajer KA, Gardner W, MacLeod B. Project ECHO: building capacity to manage complex conditions in rural, remote and underserved areas. Can J Rural Med. 2019;24:115\u201320.","journal-title":"Can J Rural Med"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-14677-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-14677-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-14677-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T07:04:24Z","timestamp":1673420664000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-14677-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["14677"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-14677-6","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ICES is an independent, non-profit research institute whose legal status under Ontario\u2019s health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement. The use of data in this project was authorized under section 45 of Ontario\u2019s Personal Health Information Protection Act without the requirement for research ethics board approval. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Melanie Penner has received consulting fees for unrelated work from Addis & Associates\/Roche and from the Government of Nova Scotia. Mina Tadrous has received consulting fees for unrelated work from Green Shield Canada and the Canadian Agency for Drugs and Technologies in Health. Tara Gomes has received funding from the Ontario MOH for unrelated work. Tony Antoniou has no competing interests. Daniel McCormack has no competing interests. Sophie Kitchen has no competing interests. Kathleen Pajer has no competing interests. William Gardner has no competing interests. Muhammad Mamdani has no competing interests. Yona Lunsky has no competing interests. David Juurlink has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}